Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2028

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab

Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.

Trial Locations (2)

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV